Heparin neutralization with platelet factor 4
AssigneeRepligen Corporation
InventorsJacquelynn J. Cook, Stefan Niewarowski, Theodore E. Maione
Life of this patent
Estimating the term…
Abstract
Circulating heparin in a mammal may be neutralized without substantial depletion of platelets or leukocytes by administering to the mammal a heparin neutralizing amount of purified PF4 or rPF4 or a heparin neutralizing fragment thereof.
Claims19
A method for completely preventing heparin inhibition of coagulation in a mammal having an undesirably high level of circulating heparin following administration of heparin in connection with a medical procedure, said method comprising administering to said mammal a heparin neutralizing amount of purified PF4 or purified recombinant PF4.
A method of restoring a normal coagulation status in a human patient after administration of heparin, without substantial depletion of platelets or leukocytes, comprising administering purified PF4 or purified recombinant PF4 to said patient to form a complex of said heparin with said PF4.
A method of treating a human patient to temporarily prevent blood coagulation during a medical procedure, comprising:
- administering to said patient a therapeutically effective amount of heparin to inhibit coagulation, and thereafter
- administering to said patient a therapeutically effective amount of purified PF4 or purified recombinant PF4 to neutralize said heparin.
Dependencies are inferred from the claim text.